Navigation Links
Data Presented at Society for Neuro-Oncology Annual Meeting Demonstrate Tocagen's Toca 511 Gene Therapy with Toca FC was Well Tolerated and Showed Antitumor Activity in Patients with High Grade Glioma
Date:11/26/2013

groups. Since radiation therapy and temozolomide are part of standard therapy for patients with newly diagnosed GBM, these data provide support for clinical investigation of Toca 511 and Toca FC in first line therapy.

"I am pleased with the progress we have made with our clinical programs, and the available survival data provide optimism for subsequent dose groups in these studies," said Harry Gruber, M.D., CEO of Tocagen. "The results from our ongoing clinical studies, taken together with the depth of our preclinical research, provide momentum for the continued investigation of this novel gene therapy for patients with brain cancer."

Data from preclinical brain cancer studies also presented at the conference demonstrate the feasibility of intravenous administration of Toca 511 as a potential complement to the current intra-tumoral delivery methods. An investigational trial was recently initiated to evaluate intravenous delivery of Toca 511 in combination with courses of oral Toca FC in patients with recurrent HGG (NCT01985256). In the future, Toca 511 may be investigated for the treatment of additional types of cancers beyond brain cancer, including metastatic cancers.

About Toca 511 and Toca FC

The combination of Toca 511 (vocimagene amiretrorepvec) for injection and Toca FC (flucytosine) extended-release tablets, is being investigated in Phase I studies at leading centers across the United States in patients with recurrent high grade glioma, including glioblastoma multiforme (GBM). Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a prodrug activator gene called cytosine deaminase (CD) selectively to cancer cells. After allowing time for Toca 511 to spread through the tumor, those cancer cells expressing the CD gene can convert the antibiotic drug flucytosine into the a
'/>"/>

SOURCE Tocagen Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
4. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
7. CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
10. Body Monitors Deliver Better Weight Loss Results at Half the Cost: Study to Be Presented at ACSM Meeting
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... 2014  Eli Lilly and Company (NYSE: LLY)  ... -- being studied for the treatment of systemic ... due to insufficient efficacy in two pivotal Phase ... safety concerns. ­­­­ In the ILLUMINATE ... endpoint, at either dose studied, of statistically significant ...
(Date:10/2/2014)... plc (NYSE: PRGO ; TASE), a public limited ... (the " Company "), today announced the expiration of ... of its new 1.30% Senior Notes due 2016 (the " ... Notes due 2018 (the " 2018 Exchange Notes "), $800,000,000 ... 2023 Exchange Notes ") and $400,000,000 of its new 5.30% ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 2Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4
... 5, 2007 - Australian,biotechnology company Avexa (ASX:AVX) announced ... which,represents the first 24 week segment of its ... open-label section of the,trial (weeks 24 to 48) ... day as part of their daily treatment regime.,The ...
... Primary endpoint achieved -- , LAINATE, Italy - ... today positive preliminary results from its,phase II/III study ... is a broad spectrum, semi-synthetic,antibiotic that is not ... of Cosmo's MMX(tm) technology, which delivers the active,ingredient ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:10/2/2014)... PA (PRWEB) October 02, 2014 ... of the 2014 BIG Awards for Business program. ... and organizations with a proprietary judging process scored ... around the globe. , “The winners this year ... Russ Fordyce, Managing Director of the Business Intelligence ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... a neurotic personality style and prolonged stress may have ... suggests. Tracking 800 women over nearly four decades, ... jealous and moody -- which they defined as neurotic ... of developing Alzheimer,s compared to women scoring lowest in ...
(Date:10/2/2014)... By Steven Reinberg ... -- Living close to a major highway may raise your ... Among more than 5,000 postmenopausal women, those who lived within ... greater risk of developing high blood pressure than women living ... "The results of this study highlight the importance of our ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... have a total of 500 confirmed cases of Enterovirus D68, ... since the summer, U.S. health officials reported Wednesday. Four ... but it,s not clear what role -- if any -- ... officials are also trying to determine if the virus is ...
(Date:10/1/2014)... team of scientists has shown that more than 80 ... existing drugs. , The study found that medicines called ... a genetic mutation that is present in more than ... are currently used, or are in clinical trials, for ... disorders. , Bowel cancer is the second-most common cancer ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... Nov. 19 Gen-Probe Incorporated,(Nasdaq: GPRO ) ... as senior vice president, operations. "We are ... and,supply chain management to our already strong senior ... and chief operating,officer. Ms. Ellerbrock, 46, joins ...
... up on a study that found widespread failures in ... team from the Johns Hopkins Childrens Center and Duke ... more than a mock trauma drill to diagnose the ... sharp again. Their report appears in the November issue ...
... rose , , MONDAY, Nov. 19 (HealthDay News) -- A new ... on the body, which may explain why people of lower ... report. , The link between higher levels of inflammatory molecules ... by poor diet and lack of exercise, the study suggests. ...
... are adding to the obesity crisis its fruit drinks, ... of North Carolina at Chapel Hill School of Public Health ... cider are abundant, the problem can be even more apparent. ... adults get through beverages has nearly doubled, according to a ...
... PHILADELPHIA According to a study that appears in ... Neuroscience), researchers at the University of Pennsylvania School of ... neural responses to psychological stress. , We ... different spatial and temporal profiles for men and women ...
... 2007 Campaign highlighted by new partnership with the NFL ... Romano, Antonio Banderas, New Orleans Saints, Reggie Bush and Marlo ... will also launch in ... Jude Children,s Research Hospital,has launched its 2007 Thanks and Giving ...
Cached Medicine News:Health News:Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations 2Health News:'Mock' drills boost child resuscitation skills in 'failing' adult emergency rooms 2Health News:'Mock' drills boost child resuscitation skills in 'failing' adult emergency rooms 3Health News:Researchers Spot Link Between Heart Disease, Income 2Health News:Doubled calorie intake from beverages likely contributes to adult obesity 2Health News:Doubled calorie intake from beverages likely contributes to adult obesity 3Health News:Penn researchers use brain imaging to demonstrate how men and women cope differently under stress 2Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 2Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 3Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 4Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 5Health News:Marlo Thomas and St. Jude Children's Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season 6
Diamond Point Bone Probe with Ortho-Grip® silicone rubber palm style handles and,stainless steel impactor caps....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Steroid eluting pacemaker leads...
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: